StageZero Life Sciences Ltd.
TTSX:SZLSShare Statistics
As of September 30, 2023, StageZero Life Sciences Ltd. has 123.55M shares outstanding.
| Shares Outstanding | 123.55M |
Valuation Ratios
These figures are as of September 30, 2023. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at -0.60.
| PS Ratio | 1.78 |
| PB Ratio | -0.60 |
| P/TBV Ratio | -0.60 |
| P/FCF Ratio | -6.46 |
| P/OCF Ratio | -6.46 |
Enterprise Valuation
These figures are as of September 30, 2023. The EV/Sales ratio of 2.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.
| EV / Sales | 2.27 |
Financial Position
As of September 30, 2023, StageZero Life Sciences Ltd. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -14.97, indicating conservative leverage, while an interest coverage ratio of -13.26 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.04 |
| Quick Ratio | 0.01 |
| Debt / Equity | -14.97 |
| Debt / EBITDA | -0.31 |
| Interest Coverage | -13.26 |
Financial Efficiency
These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -281.22, reflecting losses generated across the asset base. Inventory turnover of 21.23 indicates how many times StageZero Life Sciences Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -281.22 |
| Inventory Turnover | 21.23 |
Margins
Over the twelve months ended September 30, 2023, StageZero Life Sciences Ltd. posted a gross margin of 7.47, reflecting its pricing power and cost economics. The operating margin of -153.57 and net profit margin of -418.65 provide insight into operational efficiency.
| Gross Margin | 7.47 |
| Operating Margin | -153.57 |
| Pretax Margin | -418.65 |
| Profit Margin | -418.65 |
| EBITDA Margin | -144.12 |
Dividends & Yields
These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -15.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.16, meaning StageZero Life Sciences Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -15.16 |
| FCF Yield | -15.47 |
Stock Splits
StageZero Life Sciences Ltd.'s most recent stock split took place on September 18, 2020 with a 8:1 split ratio.
| Last Split Date | 9/18/2020 |
| Split Ratio | 8:1 |
Scores
As of September 30, 2023, StageZero Life Sciences Ltd. has an Altman Z-Score of -389.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -389.52 |